Can we measure long-term treatment effects in multiple sclerosis?

Area of Science:

• Neurology
• Clinical Trials
• Epidemiology

Background:

• Randomized controlled trials (RCTs) are the gold standard for evaluating treatment efficacy.
• Long-term assessment of multiple sclerosis (MS) treatments relies on trial extensions or observational studies.
• Observational studies are prone to selection bias due to non-random intervention assignment.

Purpose of the Study:

• To discuss methodological challenges in assessing long-term treatment effects in MS.
• To analyze how these challenges are managed in studies of IFN-β in MS patients.

Main Methods:

• Discusses limitations of observational studies, including selection bias.
• Explains propensity score methods for mitigating bias in observational data.
• Highlights the strengths of clinical trial extensions in avoiding selection bias.

Main Results:

• Propensity scores can balance covariates but not unmeasurable confounders.
• Trial extensions eliminate selection bias but assess only early vs. delayed effects.
• Analysis of IFN-β studies in MS demonstrates management of methodological issues.

Conclusions:

• Careful consideration of study design is crucial for accurate long-term treatment effect assessment in MS.
• Both trial extensions and propensity score methods offer partial solutions to methodological limitations.
• Further research is needed to fully address confounding in long-term MS treatment studies.